Ranbaxy Labs brings record breaking CB

Fierce competition for mandate results in deal having to be sold below par.

IndiaÆs Ranbaxy Laboratories has raised $440 million, including a $40 million greenshoe, from an aggressively priced five-year convertible bond that will be used for potential future acquisitions and capex.

The five-year deal, which was jointly arranged by Citigroup, Deutsche Bank, Morgan Stanley and UBS, is the second largest CB out of India after HDFCÆs $500 million bond last year and the largest ever from an Indian pharma company.

Ranbaxy is IndiaÆs largest pharmaceutical company and ranks among the...

To continue reading, please login or register for free

Click for more on: cb | pharmaceutical

Print Edition

FinanceAsia Print Edition